| 3.3 0.14 (4.43%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.57 |
1-year : | 5.34 |
| Resists | First : | 3.92 |
Second : | 4.57 |
| Pivot price | 2.89 |
|||
| Supports | First : | 3.02 |
Second : | 2.47 |
| MAs | MA(5) : | 3.18 |
MA(20) : | 2.87 |
| MA(100) : | 2.78 |
MA(250) : | 2.78 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.8 |
D(3) : | 75.3 |
| RSI | RSI(14): 58.1 |
|||
| 52-week | High : | 5 | Low : | 1.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LPTX ] has closed below upper band by 11.8%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.46 | 3.46 - 3.48 |
| Low: | 2.83 - 2.85 | 2.85 - 2.87 |
| Close: | 3.26 - 3.3 | 3.3 - 3.33 |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Tue, 26 Nov 2024
Leap Therapeutics CEO to Present at Piper Sandler Healthcare Conference - StockTitan
Tue, 26 Nov 2024
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Fri, 15 Nov 2024
HC Wainwright Reaffirms Buy Rating for Leap Therapeutics (NASDAQ:LPTX) - MarketBeat
Fri, 15 Nov 2024
Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Thu, 14 Nov 2024
Balyasny Asset Management L.P. Reduces Stake in Leap Therapeutics Inc - GuruFocus.com
Wed, 13 Nov 2024
Leap Therapeutics Reports Wider Q3 Loss, Advances Cancer Drug Trials with $62.8M Cash | LPTX Stock News - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 17.2 (%) |
| Held by Institutions | 40.2 (%) |
| Shares Short | 1,010 (K) |
| Shares Short P.Month | 899 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -80.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -2.02 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|